Latest Content

A groundbreaking at-home brain stimulation device gains FDA approval, offering hope for adults with major depressive disorder through innovative treatment.

Valproate's role in treating bipolar disorder is questioned as evidence suggests better alternatives exist for managing acute mania and maintenance.

Explore the psychological impact of Pantone's 2026 color choice, "Cloud Dancer," and its implications for emotional well-being and societal unity.

Postoperative delirium often goes unrecognized, especially in older patients. Early detection and intervention are crucial for better outcomes.

New research suggests semaglutide may protect against lithium-induced renal injury, offering hope for safer bipolar disorder treatments.

Explore how transcranial magnetic stimulation enhances athletic performance and mental health, offering innovative solutions for athletes facing psychological challenges.

"But when I finally learned to feel everything, I became a psychiatrist who touches nothing but a patient’s hand at the first meeting and the final good bye..."

Tris Pharma's TRN-257, a low-sodium oxybate, offers a once-nightly treatment option for narcolepsy and idiopathic hypersomnia, enhancing patient care.

Psychiatric Times celebrates 40 years of impactful insights, exploring key topics in psychiatry, including medication management and emerging treatments.

Teva Pharmaceuticals has submitted an NDA to the FDA for extended-release injectable olanzapine for the treatment of schizophrenia.

Dr. Carrie Soloway's legacy inspires courage in transgender individuals, highlighting the ongoing challenges and triumphs in mental health and identity.

Recent trials reveal oral semaglutide fails to improve cognition or function in early Alzheimer disease, raising questions about its efficacy.

Newron Pharmaceuticals launches a pivotal study on evenamide, targeting treatment-resistant schizophrenia to improve patient outcomes and address unmet needs.